Evidence map›Paper›PMID 36869968›Full record

ArticleClinical and experimental medicine2023

Elevated checkpoint inhibitor expression and Treg cell number in autosomal dominant polycystic kidney disease and their correlation with disease parameters and hypertension.

Ali Sahin, Ismail Kocyigit, Kubra Aslan, Eray Eroglu, Alparslan Demiray, Ahmet Eken

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical and experimental medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Ali SahinDivision of Nephrology, Department of Internal Medicine, Erciyes University School of Medicine, 38030, Kayseri, Turkey.ORCID http://orcid.org/0000-0001-8346-7535
Ismail KocyigitDivision of Nephrology, Department of Internal Medicine, Erciyes University School of Medicine, 38030, Kayseri, Turkey. iikocyigit@gmail.com.ORCID http://orcid.org/0000-0002-6654-4727
Kubra AslanDepartment of Medical Biology, Erciyes University School of Medicine, 38030, Kayseri, Turkey.ORCID http://orcid.org/0000-0003-2600-5945
Eray ErogluDepartment of Nephrology, Kilis State Hospital, Kilis, Turkey.ORCID http://orcid.org/0000-0003-2571-7385
Alparslan DemirayDivision of Nephrology, Department of Internal Medicine, Erciyes University School of Medicine, 38030, Kayseri, Turkey.ORCID http://orcid.org/0000-0002-6305-3201
Ahmet EkenDepartment of Medical Biology, Erciyes University School of Medicine, 38030, Kayseri, Turkey. ahmet.eken@gmail.com.ORCID http://orcid.org/0000-0002-5816-0686
Erciyes University · TRKilis 7 Aralık University · TR

Funding

Erciyes University BAP TTU-2020-9771
6 · The paper itself

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) has cancer-like pathophysiology. In this study, we aimed to investigate the phenotype of peripheral blood (PB) T cell subsets and immune checkpoint inhibitor expression of ADPKD patients across different chronic kidney disease (CKD) stages. Seventy-two patients with ADPKD and twenty-three healthy controls were included in the study. The patients were grouped into five different CKD stages, according to glomerular filtration rate (GFR). PB mononuclear cells were isolated and T cell subsets and cytokine production were examined by flow cytometry. CRP levels, height-adjusted total kidney volume (htTKV), rate of hypertension (HT) differed significantly across different GFR stages in ADPKD. T cell phenotyping revealed significantly elevated CD3+ T cells, CD4+, CD8+, double-negative, and double-positive subsets and significantly elevated IFN-γ and TNF-α producing subsets of CD4+, CD8+ cells. The expression of checkpoint inhibitors CTLA-4, PD-1, and TIGIT by T cell subsets was also increased to various extent. Additionally, Treg cell numbers and suppressive markers CTLA-4, PD-1, and TIGIT were significantly elevated in ADPKD patients' PB. Treg CTLA4 expression and CD4CD8DP T cell frequency in patients with HT were significantly higher. Lastly, HT and increased htTKV and higher frequency of PD1+ CD8SP were found to be risk factors for rapid disease progression. Our data provide the first detailed analyses of checkpoint inhibitor expression by PB T cell subsets during stages of ADPKD, and that a higher frequency of PD1+ CD8SP cells is associated with rapid disease progression.

Indexed as

HypertensionPolycystic Kidney, Autosomal DominantRenal Insufficiency, ChronicCell CountCTLA-4 AntigenDisease ProgressionGlomerular Filtration RateHumansKidneyProgrammed Cell Death 1 ReceptorT-Lymphocytes, RegulatoryCTLA-4 AntigenProgrammed Cell Death 1 ReceptorAutosomal dominant polycystic kidney diseaseCheckpoint inhibitorsHypertensionT cell subsets

Identifiers

PMID36869968
OpenAlexW4323050335

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.